SCHEMBL1410152

SCHEMBL1410152

CCC(=Cc1ccc(-c2cccc(C(F)(F)F)c2)o1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.62
ALDH1A1 P00352 4/20 0.62
TP53 P04637 2/20 0.59
RXFP1 Q9HBX9 1/20 0.59
MAPT P10636 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
HPGD P15428 3/20 0.52
LMNA P02545 2/20 0.49
POLB P06746 2/20 0.49
THRB P10828 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HTT P42858 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
RXRA P19793 1/20 0.47
GAA P10253 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.47
NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1410414 0.89 KDM4E (0.47) KDM4EALDH1A1TP53RXFP1MAPT
SCHEMBL1410593 0.85 TP53 (0.44) KDM4EALDH1A1TP53RXFP1MAPT
SCHEMBL1410277 0.82 RXRA (0.47) KDM4EALDH1A1TP53RXFP1MAPT
SCHEMBL1410092 0.81 MAPT (0.40) KDM4EALDH1A1TP53RXFP1MAPT
SCHEMBL19559184 0.80 KDM4E (0.62) KDM4EALDH1A1TP53RXFP1MAPT
SCHEMBL1409530 0.78 PSEN1 (0.42) KDM4EALDH1A1TP53RXFP1MAPT
SCHEMBL14300748 0.77 KDM4E (1.00) KDM4EALDH1A1TP53MAPTMEN1
SCHEMBL14300749 0.77 KDM4E (1.00) KDM4EALDH1A1TP53MAPTMEN1
SCHEMBL1410158 0.76 EPHX2 (0.41) KDM4EALDH1A1TP53RXFP1MAPT
SCHEMBL5094454 0.76 EPHX2 (0.55) ALDH1A1MAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251187-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251187-A1 HETEROCYCLIC COMPOUND NES, BMI1, DOT1L KDM4E 641/4885ALDH1A1 270/4885TP53 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.